Secondly, as a reduction in EGFR expression as a result of melittin treatment has never been reported in lung cancer cells, this could be because EGFR in lung cancer cells is highly expressed [30], potentially leading to a reduced sensitivity to melittin-induced effects. The gene discussed is EGFR; the disease is lung carcinoma.